Investigation of Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
The goal of this observational study is to learn about in patients with advanced hepatocellular carcinoma treated with atezoliozumab and bevacizumab. In this clinical study, we intend to analyze the multiomics data by analyzing the peripheral blood and tumor tissue before and after treatment of patients with advanced liver cancer receiving systemic drug treatment, and analyzing the correlation with the treatment. This is an exploratory study that aims to discover biomarkers that are highly correlated with treatment response.
• Those above the age of 20 who understand the purpose of the study and agree to participate in the collection of samples during the study.
• Patients who have been diagnosed with unresectable advanced HCC through imaging, histological, or cytological tests.
• Patients who underwent an NGS test with advanced HCC tissues
• Patients planning to receive atezolizumab and bevacizumab combination therapy
• Patients with measurable lesions based on RECIST v1.1
• ECOG performance status 0 or 1
• Patients with a life expectancy of at least three months
• Those above the age of 20 who understand the purpose of the study and agree to participate in the collection of samples during the study.
• Patients who have been diagnosed with unresectable advanced HCC through imaging, histological, or cytological tests.
• Patients who underwent an NGS test with advanced HCC tissues
• Patients have received atezolizumab and bevacizumab combination therapy
• Patients with measurable lesions based on RECIST v1.1
• ECOG performance status 0 or 1
• Patients with a life expectancy of at least three months